StockMacro
Company, fund or insider

Help

Menu

Vor Biopharma

$19.19 +36% in 6 monthsMarket cap $1.2B

VOR on XNAS, Health Care, Vor Biopharma Inc., job postings

Measures activity, not value. Not investment advice.

Reported net profit of $1.4B but free cash flow was -$119.7M; shares up 180% in a year.

  • BadShort interest 12% of shares, 9.9 days to cover
  • GoodNew institutional positions 61, 5.5 times a year earlier

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
76
Website
vorbio.com
Listed
Nasdaq, US
Last results
12 Jan 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $86.7M.
Quarter to 31 Dec 2021: revenue –, net income -$18.3MQuarter to 31 Mar 2022: revenue –, net income -$22.7MQuarter to 30 Jun 2022: revenue –, net income -$21.7MQuarter to 30 Sep 2022: revenue –, net income -$23.8MQuarter to 31 Dec 2022: revenue –, net income -$23.9MQuarter to 31 Mar 2023: revenue –, net income -$28.4MQuarter to 30 Jun 2023: revenue –, net income -$30.0MQuarter to 30 Sep 2023: revenue –, net income -$33.2MQuarter to 31 Dec 2023: revenue –, net income -$26.3MQuarter to 31 Mar 2024: revenue –, net income -$30.8MQuarter to 30 Jun 2024: revenue –, net income -$27.8MQuarter to 30 Sep 2024: revenue –, net income -$27.6MQuarter to 31 Dec 2024: revenue –, net income -$30.7MQuarter to 31 Mar 2025: revenue –, net income -$32.5MQuarter to 30 Jun 2025: revenue –, net income -$1.6BQuarter to 30 Sep 2025: revenue –, net income -$812.7MQuarter to 31 Dec 2025: revenue –, net income $1.7BQuarter to 31 Mar 2026: revenue –, net income -$219.6MQuarter to 30 Jun 2026: revenue –, net income -$62.8MQuarter to 30 Sep 2026: revenue –, net income -$86.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $1.7B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$86.7M
30 Jun 2026–-$62.8M
31 Mar 2026–-$219.6M
31 Dec 2025–$1.7B
30 Sep 2025–-$812.7M
30 Jun 2025–-$1.6B
31 Mar 2025–-$32.5M
31 Dec 2024–-$30.7M
30 Sep 2024–-$27.6M
30 Jun 2024–-$27.8M
31 Mar 2024–-$30.8M
31 Dec 2023–-$26.3M
30 Sep 2023–-$33.2M
30 Jun 2023–-$30.0M
31 Mar 2023–-$28.4M
31 Dec 2022–-$23.9M
30 Sep 2022–-$23.8M
30 Jun 2022–-$21.7M
31 Mar 2022–-$22.7M
31 Dec 2021–-$18.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $1.4B -$2.4B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$119.7M -$144.7M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $481.6M $170.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$481.6M (net cash) -$170.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Vor BiopharmaVOR (this company) $1.2B––––
Taysha Gene TherapiesTSHA $1.2Bloss221-13%–
NovavaxNVAX $1.2Bloss3.0-61%-18.6%
Inhibrx BiosciencesINBX $1.0Bloss–––
Recursion PharmaceuticalsRXRX $1.5Bloss22.4+56%-697%
Vir BiotechnologyVIR $1.6Bloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+52%

154 13F filers vs 101

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

90%

55.3M shares held by 13F filers (30 Sep 2026) of 61.4M outstanding (26 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

7.5M shares sold short (30 Oct 2026) of 61.4M outstanding (26 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

9.9

7.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+0.8%

7.4M shares sold short in the report before, 7.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

59%

59% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

28

28 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

28 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 61, 5.5× a year earlier

Price $19.19 on 20 Nov 2026, +180% over 12 months (12-month range $6.86 to $25.10)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
Insider net buying (open market). Insiders sold a net $49.4M in the last 12 months (the 12 months before: -$61.4M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Capital spending per quarter. Capital spending $25K in the latest quarter, -90% on a year earlier.
Institutional holders (13F filers). 154 13F filers reported holding it in the latest 13F quarter, +340% on a year earlier.
Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months, -100% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, federal obligations, lobbying spend.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 61 vs usual 11 (2026-09-30); 5.5x the same period a year earlier
7 Jul 20268-K and other filingsDirector or officer change
7 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 30 vs usual 10.50 (2026-03-31); 3.3x the same period a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 9.50 (2025-12-31); 2.3x the same period a year earlier
2 Jan 20268-K and other filingsDirector or officer change
18 Dec 20258-K and other filingsDirector or officer change
9 Dec 20258-K and other filingsDirector or officer change
3 Nov 20258-K and other filingsDirector or officer change
30 Sep 2025Sharp changeShort interest spike: short interest spike, 22.0M vs usual 1.5M (2025-09-15); 8.7x the same period a year earlier
16 Sep 2025Sharp changeShort interest spike: short interest spike, 19.8M vs usual 1.5M (2025-08-29); 12.7x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 18.4M vs usual 1.5M (2025-08-15); 11.1x the same period a year earlier
27 Aug 20258-K and other filingsDirector or officer change
27 Aug 20258-K and other filingsDirector or officer change
12 Aug 2025Sharp changeShort interest spike: short interest spike, 18.6M vs usual 1.5M (2025-07-31); 10.3x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 14.4M vs usual 1.5M (2025-07-15); 7.7x the same period a year earlier
22 Jul 20258-K and other filingsDirector or officer change
10 Jul 20258-K and other filingsDirector or officer change
1 Jul 2025Sharp changeShort interest spike: short interest spike, 3.2M vs usual 1.5M (2025-06-13); 0.8x the same period a year earlier
26 Jun 20258-K and other filingsDirector or officer change
26 Jun 20258-K and other filingsA major agreement ended
17 Jun 2025Sharp changeShort interest spike: short interest spike, 4.2M vs usual 1.5M (2025-05-30); 1.2x the same period a year earlier
3 Jun 2025Sharp changeShort interest spike: short interest spike, 2.8M vs usual 1.5M (2025-05-15); 0.8x the same period a year earlier
29 May 2025WARN layoff noticeVor Biopharma, Inc., 155 workers, Cambridge, MA
29 May 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 155)
20 May 20258-K and other filingsDirector or officer change
8 May 20258-K and other filingsDirector or officer change
8 May 20258-K and other filingsRestructuring costs announced
25 Apr 20258-K and other filingsDelisting notice or listing transfer
3 Apr 20258-K and other filingsDirector or officer change
6 Feb 20258-K and other filingsDirector or officer change
8 Jan 20258-K and other filingsDirector or officer change
8 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Sep 20248-K and other filingsDirector or officer change
30 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Aug 20248-K and other filingsDelisting notice or listing transfer
10 Jun 20248-K and other filingsDirector or officer change
28 May 20248-K and other filingsDirector or officer change
2 May 20248-K and other filingsDirector or officer change
2 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Aug 2023Sharp changeMany funds opening a new position: many funds opening a new position, 21 vs usual 7.50 (2023-06-30); 2.6x the same period a year earlier
14 Apr 20238-K and other filingsDirector or officer change
14 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Dec 20228-K and other filingsA major agreement ended
16 Aug 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.8M vs usual 1.2M (2022-06-30); 6.3x the same period a year earlier
14 Apr 20228-K and other filingsDirector or officer change
14 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Jun 2024: -$20K published
Month from 1 Jan 2025: -$13K published
Month from 1 Feb 2025: -$7K published
Month from 1 Aug 2025: -$4.3M published
Month from 1 Sep 2025: -$7.6M published
Month from 1 Oct 2025: -$49.5M published
Month from 1 Apr 2026: -$49.4M published
Month from 1 Jul 2026: -$4K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jul 2022: 6 published
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 2 published
Quarter from 1 Oct 2024: 2 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 5 published
Capital spending per quarter
Quarter ended 31 Dec 2020: $1.5M; public on 15 Mar 2022
Quarter ended 31 Dec 2021: $1.2M, -21% on a year earlier; public on 15 Mar 2022
Quarter ended 31 Mar 2022: $2.0M, +72% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $5.8M, +535% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $298K, -53% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $321K, -73% on a year earlier; public on 24 Mar 2023
Quarter ended 31 Mar 2023: $94K, -95% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $399K, -93% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $465K, +56% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $111K, -65% on a year earlier; public on 21 Mar 2024
Quarter ended 31 Mar 2024: $114K, +21% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $9K, -98% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $34K, -93% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $72K, -35% on a year earlier; public on 21 Mar 2025
Quarter ended 31 Mar 2025: $231K, +103% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $152K, +1589% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $244K, +618% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $314K, +336% on a year earlier; public on 31 Mar 2026
Quarter ended 31 Mar 2026: $48K, -79% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $120K, -21% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $25K, -90% on a year earlier; public on 31 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 54; public on 14 Feb 2022
31 Mar 2022 report: 56; public on 16 May 2022
30 Jun 2022 report: 47; public on 15 Aug 2022
30 Sep 2022 report: 45; public on 14 Nov 2022
31 Dec 2022 report: 54; public on 14 Feb 2023
31 Mar 2023 report: 55; public on 15 May 2023
30 Jun 2023 report: 66; public on 14 Aug 2023
30 Sep 2023 report: 57; public on 14 Nov 2023
31 Dec 2023 report: 55; public on 14 Feb 2024
31 Mar 2024 report: 65; public on 15 May 2024
30 Jun 2024 report: 68; public on 14 Aug 2024
30 Sep 2024 report: 51; public on 14 Nov 2024
31 Dec 2024 report: 51; public on 14 Feb 2025
31 Mar 2025 report: 45; public on 15 May 2025
30 Jun 2025 report: 32; public on 14 Aug 2025
30 Sep 2025 report: 35; public on 14 Nov 2025
31 Dec 2025 report: 54; public on 17 Feb 2026
31 Mar 2026 report: 78; public on 15 May 2026
30 Jun 2026 report: 101; public on 14 Aug 2026
30 Sep 2026 report: 154; public on 16 Nov 2026
Workers in WARN layoff notices
Month from 1 May 2025: 155 published

What is unusual now

  • Made public in the last 90 days: it saw 61 13F filers open a new position in the quarter ended 30 Sep 2026, 5.5× the same quarter last year.
  • Many funds opening a new position: saw 61 13F filers open a new position in the quarter ended 30 Sep 2026, 5.5× the same quarter last year Public on 16 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $49.4M in the last 12 months (the 12 months before: -$61.4M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 32 insider trades

No trades in the last 90 days; the latest was filed 21 Jul 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
21 Jul 2026Rajeev M. Shah and 3 others10% ownerSell213$19.75$4KForm 4
24 Apr 2026Rajeev M. Shah and 3 othersDirector, 10% ownerSell165,150$15.77$2.6MForm 4
21 Apr 2026Ra Capital Management, L.P. and 3 othersDirector, 10% ownerSell630,374$16.14$10.2MForm 4
15 Apr 2026Ra Capital Management, L.P. and 3 othersDirector, 10% ownerSell737,989$16.10$11.9MForm 4
10 Apr 2026Rajeev M. Shah and 3 othersDirector, 10% ownerSell620,133$16.50$10.2MForm 4
6 Apr 2026Peter Kolchinsky and 3 othersDirector, 10% ownerSell849,257$17.10$14.5MForm 4
30 Oct 2025Peter Kolchinsky and 3 othersDirector, 10% ownerSell400,408$25.90$10.4MForm 4
27 Oct 2025Ra Capital Management, L.P. and 3 othersDirector, 10% ownerSell221,166$28.06$6.2MForm 4

154 institutions reported shares at the end of Q3 2026, 90% of the shares outstanding; 60 opened a position, 12 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)6.8M11.0%$129.0M+1.8M+37%
TCG Crossover Management, LLC5.7M9.23%$108.2MNo change
Ra Capital Management, L.P.4.5M7.33%$85.9M+2.1M+87%
FCPM III Services B.V.3.4M5.54%$65.0M-712K-17%
BlackRock, Inc.3.3M5.38%$63.1M-162K-4.7%
Venrock Adviser, LLC3.0M4.95%$58.0MNo change
Frazier Life Sciences Management, L.P.2.7M4.47%$52.4M+200K+7.9%
Vanguard Capital Management LLC2.0M3.31%$38.8M-49K-2.3%
State Street Corp2.0M3.21%$37.6M-647K-25%
Caligan Partners LP1.9M3.13%$36.7MNo change

Company events

All 38 company events

In 12 months: 4 director or officer changes, 3 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
12 Nov 2026Amended and restated license agreement with RemeGen Co., Ltd. adds RC298; $10M upfront plus pre-funded warrant for 2,300,000 sharesSame filing: sold shares privately8-K
7 Jul 2026Director or officer change8-K
27 Mar 2026Signed a major agreementSame filing: sold shares privately8-K
2 Jan 2026Director or officer change8-K
18 Dec 2025Director or officer change; Signed a major agreementSame filing: sold shares privately8-K
9 Dec 2025Director or officer change8-K
3 Nov 2025Director or officer change8-K
27 Aug 2025Director or officer changeSame filing: shareholder vote results8-K

Layoff notices

All 1 layoff notices

No notice in 12 months; the latest is dated 28 May 2025. State WARN notices.

NoticeSiteWorkersJobs endSource
28 May 2025Vor Biopharma, Inc.Cambridge, MA1558 May 2025Notice

The 5 newest of 86 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

3 Jun 2025confirmed

Confirmed across sources Layoff notices and Short interest and volume

Vor Biopharma (VOR): filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA), while it had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year. Two unrelated kinds of activity within 124 days.

  • Layoff notices: WARN layoff notice, became public on 29 May 2025
  • Short interest and volume: Short interest spike, became public on 28 May 2025
  • Short interest and volume: Short interest spike, became public on 11 Jun 2025
  • Short interest and volume: Short interest spike, became public on 26 Jun 2025
  • Short interest and volume: Short interest spike, became public on 25 Jul 2025
  • Short interest and volume: Short interest spike, became public on 12 Aug 2025
  • Short interest and volume: Short interest spike, became public on 27 Aug 2025
  • Short interest and volume: Short interest spike, became public on 11 Sep 2025
  • Short interest and volume: Short interest spike, became public on 25 Sep 2025
2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M2025-08-29: 19.8M2025-09-15: 22.0M
The 15 Sep 2025 report against the 24 reports before it. this reportearliernormal: 1.5M
See the evidence (9 changes)

Layoff notices: WARN layoff notice became public on 29 May 2025

Vor Biopharma filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA).

Notices in the window
1
Workers named
155
Window
29 Apr 2025 to 29 May 2025

Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

Short interest and volume: Short interest spike became public on 28 May 2025

Vor Biopharma had 2.8M shares sold short in the 15 May 2025 report, 21% below the same report last year.

This period
2.8M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+3.9
Same report last year
3.5M
History used
1,553 days
2024-05-15: 3.5M2024-05-31: 3.6M2024-06-14: 3.8M2024-06-28: 2.8M2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M
the 15 May 2025 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Jun 2025

Vor Biopharma had 4.2M shares sold short in the 30 May 2025 report, 1.2× the same report last year.

This period
4.2M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+8.4
Same report last year
3.6M
History used
1,568 days
2024-05-31: 3.6M2024-06-14: 3.8M2024-06-28: 2.8M2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M
the 30 May 2025 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jun 2025

Vor Biopharma had 3.2M shares sold short in the 13 Jun 2025 report, 15% below the same report last year.

This period
3.2M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+5.4
Same report last year
3.8M
History used
1,582 days
2024-06-14: 3.8M2024-06-28: 2.8M2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M
the 13 Jun 2025 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Jul 2025

Vor Biopharma had 14.4M shares sold short in the 15 Jul 2025 report, 7.7× the same report last year.

This period
14.4M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+40.1
Same report last year
1.9M
History used
1,614 days
2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M
the 15 Jul 2025 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Aug 2025

Vor Biopharma had 18.6M shares sold short in the 31 Jul 2025 report, 10× the same report last year.

This period
18.6M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+53.2
Same report last year
1.8M
History used
1,630 days
2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M
the 31 Jul 2025 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Aug 2025

Vor Biopharma had 18.4M shares sold short in the 15 Aug 2025 report, 11× the same report last year.

This period
18.4M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+52.7
Same report last year
1.7M
History used
1,645 days
2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M
the 15 Aug 2025 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Sep 2025

Vor Biopharma had 19.8M shares sold short in the 29 Aug 2025 report, 13× the same report last year.

This period
19.8M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
247K
How far from its usual level
+49.9
Same report last year
1.6M
History used
1,659 days
2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M2025-08-29: 19.8M
the 29 Aug 2025 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Sep 2025

Vor Biopharma had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year.

This period
22.0M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
306K
How far from its usual level
+45.2
Same report last year
2.5M
History used
1,676 days
2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M2025-08-29: 19.8M2025-09-15: 22.0M
the 15 Sep 2025 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 61 13F filers open a new position in the quarter ended 30 Sep 2026, 5.5× the same quarter last year.

    Same quarter last year: 11; its normal quarter is 11.

    See the evidence
    This period
    61 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    11
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +13.5
    Same quarter last year
    11
    History used
    2,009 days
    2024-09-30: 92024-12-31: 112025-03-31: 92025-06-30: 82025-09-30: 112025-12-31: 252026-03-31: 302026-06-30: 362026-09-30: 61
    the quarter ended 30 Sep 20268 earlier quartersnormal: 11

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 7 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 7 Jul 2026Filings record

    Director or officer change

  4. 15 May 2026Institutional holdings change

    saw 30 13F filers open a new position in the quarter ended 31 Mar 2026, 3.3× the same quarter last year.

    Same quarter last year: 9; its normal quarter is 10.5.

    See the evidence
    This period
    30 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    10.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +6.5
    Same quarter last year
    9
    History used
    1,826 days
    2024-03-31: 102024-06-30: 202024-09-30: 92024-12-31: 112025-03-31: 92025-06-30: 82025-09-30: 112025-12-31: 252026-03-31: 30
    the quarter ended 31 Mar 20268 earlier quartersnormal: 10.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  5. 17 Feb 2026Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, 2.3× the same quarter last year.

    Same quarter last year: 11; its normal quarter is 9.5.

    See the evidence
    This period
    25 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    9.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +5.2
    Same quarter last year
    11
    History used
    1,736 days
    2023-12-31: 52024-03-31: 102024-06-30: 202024-09-30: 92024-12-31: 112025-03-31: 92025-06-30: 82025-09-30: 112025-12-31: 25
    the quarter ended 31 Dec 20258 earlier quartersnormal: 9.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  6. 2 Jan 2026Filings record

    Director or officer change

  7. 18 Dec 2025Filings record

    Director or officer change

  8. 9 Dec 2025Filings record

    Director or officer change

  9. 3 Nov 2025Filings record

    Director or officer change

  10. 25 Sep 2025Short interest and volume change

    had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year.

    Same report last year: 2.5M; its normal report is 1.5M.

    See the evidence
    This period
    22.0M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    306K
    How far from its usual level
    +45.2
    Same report last year
    2.5M
    History used
    1,676 days
    2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M2025-08-29: 19.8M2025-09-15: 22.0M
    the 15 Sep 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 11 Sep 2025Short interest and volume change

    had 19.8M shares sold short in the 29 Aug 2025 report, 13× the same report last year.

    Same report last year: 1.6M; its normal report is 1.5M.

    See the evidence
    This period
    19.8M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    247K
    How far from its usual level
    +49.9
    Same report last year
    1.6M
    History used
    1,659 days
    2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M2025-08-29: 19.8M
    the 29 Aug 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 27 Aug 2025Short interest and volume change

    had 18.4M shares sold short in the 15 Aug 2025 report, 11× the same report last year.

    Same report last year: 1.7M; its normal report is 1.5M.

    See the evidence
    This period
    18.4M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +52.7
    Same report last year
    1.7M
    History used
    1,645 days
    2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M
    the 15 Aug 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 27 Aug 2025Filings record

    Director or officer change

  14. 27 Aug 2025Filings record

    Director or officer change

  15. 12 Aug 2025Short interest and volume change

    had 18.6M shares sold short in the 31 Jul 2025 report, 10× the same report last year.

    Same report last year: 1.8M; its normal report is 1.5M.

    See the evidence
    This period
    18.6M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +53.2
    Same report last year
    1.8M
    History used
    1,630 days
    2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M
    the 31 Jul 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 25 Jul 2025Short interest and volume change

    had 14.4M shares sold short in the 15 Jul 2025 report, 7.7× the same report last year.

    Same report last year: 1.9M; its normal report is 1.5M.

    See the evidence
    This period
    14.4M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +40.1
    Same report last year
    1.9M
    History used
    1,614 days
    2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M
    the 15 Jul 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 22 Jul 2025Filings record

    Director or officer change

  18. 10 Jul 2025Filings record

    Director or officer change

  19. 26 Jun 2025Short interest and volume change

    had 3.2M shares sold short in the 13 Jun 2025 report, 15% below the same report last year.

    Same report last year: 3.8M; its normal report is 1.5M.

    See the evidence
    This period
    3.2M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +5.4
    Same report last year
    3.8M
    History used
    1,582 days
    2024-06-14: 3.8M2024-06-28: 2.8M2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M
    the 13 Jun 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 26 Jun 2025Filings record

    Director or officer change (dated 25 Jun 2025)

  21. 26 Jun 2025Filings record

    A major agreement ended (dated 25 Jun 2025)

  22. 11 Jun 2025Short interest and volume change

    had 4.2M shares sold short in the 30 May 2025 report, 1.2× the same report last year.

    Same report last year: 3.6M; its normal report is 1.5M.

    See the evidence
    This period
    4.2M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +8.4
    Same report last year
    3.6M
    History used
    1,568 days
    2024-05-31: 3.6M2024-06-14: 3.8M2024-06-28: 2.8M2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M
    the 30 May 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 3 Jun 2025several at once

    filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA), while it had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year. Two unrelated kinds of activity within 124 days.

    See the evidence (9 changes)

    Layoff notices: WARN layoff notice became public on 29 May 2025

    Vor Biopharma filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA).

    Notices in the window
    1
    Workers named
    155
    Window
    29 Apr 2025 to 29 May 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

    Short interest and volume: Short interest spike became public on 28 May 2025

    Vor Biopharma had 2.8M shares sold short in the 15 May 2025 report, 21% below the same report last year.

    This period
    2.8M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +3.9
    Same report last year
    3.5M
    History used
    1,553 days
    2024-05-15: 3.5M2024-05-31: 3.6M2024-06-14: 3.8M2024-06-28: 2.8M2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M
    the 15 May 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Jun 2025

    Vor Biopharma had 4.2M shares sold short in the 30 May 2025 report, 1.2× the same report last year.

    This period
    4.2M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +8.4
    Same report last year
    3.6M
    History used
    1,568 days
    2024-05-31: 3.6M2024-06-14: 3.8M2024-06-28: 2.8M2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M
    the 30 May 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Jun 2025

    Vor Biopharma had 3.2M shares sold short in the 13 Jun 2025 report, 15% below the same report last year.

    This period
    3.2M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +5.4
    Same report last year
    3.8M
    History used
    1,582 days
    2024-06-14: 3.8M2024-06-28: 2.8M2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M
    the 13 Jun 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Jul 2025

    Vor Biopharma had 14.4M shares sold short in the 15 Jul 2025 report, 7.7× the same report last year.

    This period
    14.4M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +40.1
    Same report last year
    1.9M
    History used
    1,614 days
    2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M
    the 15 Jul 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Aug 2025

    Vor Biopharma had 18.6M shares sold short in the 31 Jul 2025 report, 10× the same report last year.

    This period
    18.6M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +53.2
    Same report last year
    1.8M
    History used
    1,630 days
    2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M
    the 31 Jul 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Aug 2025

    Vor Biopharma had 18.4M shares sold short in the 15 Aug 2025 report, 11× the same report last year.

    This period
    18.4M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +52.7
    Same report last year
    1.7M
    History used
    1,645 days
    2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M
    the 15 Aug 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Sep 2025

    Vor Biopharma had 19.8M shares sold short in the 29 Aug 2025 report, 13× the same report last year.

    This period
    19.8M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    247K
    How far from its usual level
    +49.9
    Same report last year
    1.6M
    History used
    1,659 days
    2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M2025-08-29: 19.8M
    the 29 Aug 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Sep 2025

    Vor Biopharma had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year.

    This period
    22.0M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    306K
    How far from its usual level
    +45.2
    Same report last year
    2.5M
    History used
    1,676 days
    2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M2025-05-30: 4.2M2025-06-13: 3.2M2025-06-30: 18.1M2025-07-15: 14.4M2025-07-31: 18.6M2025-08-15: 18.4M2025-08-29: 19.8M2025-09-15: 22.0M
    the 15 Sep 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  24. 29 May 2025Layoff notices change

    filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    155
    Window
    29 Apr 2025 to 29 May 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  25. 29 May 2025Layoff notices record

    WARN notice: Vor Biopharma, Inc., 155 workers, Cambridge, MA (dated 28 May 2025)

  26. 28 May 2025Short interest and volume change

    had 2.8M shares sold short in the 15 May 2025 report, 21% below the same report last year.

    Same report last year: 3.5M; its normal report is 1.5M.

    See the evidence
    This period
    2.8M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    216K
    How far from its usual level
    +3.9
    Same report last year
    3.5M
    History used
    1,553 days
    2024-05-15: 3.5M2024-05-31: 3.6M2024-06-14: 3.8M2024-06-28: 2.8M2024-07-15: 1.9M2024-07-31: 1.8M2024-08-15: 1.7M2024-08-30: 1.6M2024-09-13: 2.5M2024-09-30: 2.0M2024-10-15: 1.7M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.3M2024-12-31: 1.2M2025-01-15: 1.2M2025-01-31: 1.3M2025-02-14: 1.4M2025-02-28: 1.5M2025-03-14: 1.3M2025-03-31: 1.3M2025-04-15: 1.3M2025-04-30: 1.1M2025-05-15: 2.8M
    the 15 May 2025 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 20 May 2025Filings record

    Director or officer change

  28. 8 May 2025Filings record

    Director or officer change

  29. 8 May 2025Filings record

    Restructuring costs announced

  30. 25 Apr 2025Filings record

    Delisting notice or listing transfer

  31. 3 Apr 2025Filings record

    Director or officer change

  32. 6 Feb 2025Filings record

    Director or officer change

  33. 8 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 8 Jan 2025Filings record

    Director or officer change

  35. 3 Jan 2025Insiders record

    Hoffman Reid (ten percent owner) and 1 other(s) bought 38,974,101 shares of VOR (dated 2 Jan 2025)

  36. 30 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 30 Sep 2024Filings record

    Director or officer change

  38. 30 Aug 2024Filings record

    Delisting notice or listing transfer

  39. 10 Jun 2024Filings record

    Director or officer change

  40. 28 May 2024Filings record

    Director or officer change

Showing the newest 40 of 56 entries; narrow the window or the kind of data to see older ones.

Not listed: 76 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001817229
Ticker
VOR
Domain
vorbio.com
Employer name
Vor Biopharma, Inc. (1 unverified)
Hq location
MA|BOSTON|02116 (1 unverified)
Name
Vor Biopharma Inc.
  • DOL H-1B labor condition applications and PERM certifications127 data points11 May 2020 to 9 Jun 2025
  • SEC Form 13F institutional holdings207 data points31 Mar 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)78 records10 Jul 2020 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)380 data points31 Dec 2019 to 26 Oct 2026
  • SEC Form 4 insider transactions32 records, 112 data points9 Feb 2021 to 21 Jul 2026
  • FINRA short interest (twice monthly)410 data points12 Feb 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2912 data points5 Feb 2021 to 20 Nov 2026
  • WARN layoff notices (state labor agencies)1 record, 3 data points26 May 2025 to 28 May 2025